As noted in the pooled cancer dataset, AA patients received more treatment per patient than W patients in the Outpatient setting for both ER/PR+ and ER/PR− cancers and Her2− and Her2+ cancers and the converse; AA patients received less treatment per patient than W patients in every receptor category in the NCH setting. Here, ERBB2 is linked to cancer.